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ABSTRACT
Currently, the lack of a universal and specific marker of clonality hampers 
the diagnosis and classification of chronic expansions of natural killer (NK) cells. 
Here we investigated the utility of flow cytometric detection of aberrant/altered 
NK-cell phenotypes as a surrogate marker for clonality, in the diagnostic work-up 
of chronic lymphoproliferative disorders of NK cells (CLPD-NK). For this purpose, 
a large panel of markers was evaluated by multiparametric flow cytometry on 
peripheral blood (PB) CD56low NK cells from 60 patients, including 23 subjects 
with predefined clonal (n = 9) and polyclonal (n = 14) CD56low NK-cell expansions, 
and 37 with CLPD-NK of undetermined clonality; also, PB samples from 10 healthy 
adults were included. Clonality was established using the human androgen receptor 
(HUMARA) assay. Clonal NK cells were found to show decreased expression of CD7, 
CD11b and CD38, and higher CD2, CD94 and HLADR levels vs. normal nk cells, 
together with a restricted repertoire of expression of the CD158a, CD158b and 
CD161 killer-associated receptors. In turn, NK cells from both clonal and polyclonal 
CLPD-NK showed similar/overlapping phenotypic profiles, except for high and 
more homogeneous expression of CD94 and HLADR, which was restricted to clonal 
CLPD-nk. We conclude that the CD94hi/HLADR+ phenotypic profile proved to be a 
useful surrogate marker for NK-cell clonality.
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INTRODUCTION
Chronic lymphoproliferative disorders (CLPD) of 
natural killer (NK) cells (CLPD-NK) are a relatively 
rare and heterogeneous group of diseases characterized 
by a persistent (> 6 months) increase of mature-
appearing NK cells (> 2 × 109/L) in peripheral blood 
(PB), in the absence of a clearly identifiable cause 
[1, 2, 3]. Expanded NK cells usually display a large 
granular lymphocyte (LGL) morphology and a typical 
surface-membrane CD3−, CD2+, CD16+, CD56low and 
CD57−/+ immunophenotype [4, 5]. From the clinical 
point of view, most patients present with an indolent 
course in the absence of any symptoms [1, 6, 7, 8]; 
without treatment, the number of circulating PB NK 
cells usually remains stable for long periods of time, 
and some cases have even been reported to show 
spontaneous regression [9, 10]. Actually, CLPD-NK 
have recently emerged as a new (provisional) entity 
in the WHO2008 (World Health Organization 2008) 
classification of lymphoid malignancies [11], mostly 
because of the need for distinguishing such CLPD-
NK cases from more aggressive NK-cell leukemias/
lymphomas [12].
The WHO2008 category of CLPD-NK comprises a 
broad spectrum of NK-cell expansions, ranging from reactive 
to monoclonal/neoplastic disorders, which have been 
previously denominated as chronic NK-cell lymphocytosis, 
chronic NK-large granular leukemia or NK-cell LGL 
lymphocytosis, among other terms [7, 13, 14]. Hence, a 
major challenge for the diagnosis of CLPD-NK remains 
the ability to assess the reactive (polyclonal/oligoclonal) 
vs. (mono) clonal nature of the expanded NK cells, due 
to the lack of a universal and specific marker for NK-cell 
clonality. Therefore, because clonal NK cells from CLPD-
NK typically do not show immunoglobulin or T-cell receptor 
gene rearrangements and their karyotype is normal in most 
cases [10, 13, 15], alternative methods have been used as 
surrogate markers for NK-cell clonality –including detection 
of EBV+ NK cells by Southern blotting [16, 17, 18, 19, 20], 
analysis of restriction fragment length polymorphisms 
(RLFP) and restricted (or aberrant) expression of a single 
isoform of KIR receptors [21, 22, 23, 24], the assessment 
of the pattern of inactivation of the X-chromosome (e.g. 
the human androgen receptor assay –HUMARA-) [25, 26] 
and more recently, the presence of STAT3 mutations [27]; 
however, these approaches only proved to work in a fraction 
of patients with chronic NK-cell expansions [18, 19, 20, 
23, 24], or they showed inconclusive results [22, 27, 28, 
29]. Therefore, since a universal and specific marker for 
NK-cell clonality is still lacking, precise definition of those 
immunophenotypic profiles specifically associated with NK-
cell clonality, could contribute to the distinction between 
reactive and clonal CLPD-NK.
In the present study we investigated the 
immunophenotypic profile of expanded NK cells from 
23 females (selected from a total of 60 patients) with 
predefined monoclonal and polyclonal CLPD of CD56low 
NK cells vs. that of normal PB NK cells, using a large 
panel of 26 markers analyzed by multiparameter flow 
cytometry; ultimately, we aimed at identifying aberrant 
immunophenotypes that could be used as surrogate 
markers for NK cell clonality. Overall, our results showed 
that despite multiple immunophenotypic differences 
existed between normal and expanded CD56low NK cells, 
the distinction between monoclonal and polyclonal NK 
cells mostly relied on a strong and more homogeneous 
pattern of expression of HLADR and CD94, typically 
restricted to clonal CLPD-NK.
RESULTS
Clinical and laboratory characteristics of 
patients with monoclonal vs. polyclonal 
expansions of PB CD56low NK-cells
From the 23 female patients who were heterozygous 
for the HUMARA assay, 9 were classified as having 
monoclonal and 14 as polyclonal NK-cell expansions. 
Analysis of somatic mutations of the signal transducer 
and activator of transcription 3 and 5b genes (STAT3 and 
STAT5b) were consistent with the HUMARA assay, as the 
hotspot D661Y (c.1981G > T) mutation at the SH2 (exon 
21) domain of STAT3 was detected in 1/4 cases carrying 
clonal NK cells, while no mutations were found in any 
of the polyclonal cases screened for STAT3 and STAT5b 
genes (n = 5).
From the clinical point of view, no statistically 
significant differences were found between the polyclonal 
and monoclonal cases. Briefly, both groups showed 
indolent disease, in the absence of organomegalies, 
recurrent infections, associated neoplasias and/or 
autoimmune disorders, except for two monoclonal 
CD56low NK-cell cases, who presented skin lesions, 
associated in one of them with immune thrombocytopenia 
(Table 1).
Despite the above referred similarities, all cases 
with monoclonal CD56low NK cells had lymphocytosis 
> 3 × 109/L at presentation, while this occurred in 
only 58% of cases with polyclonal CD56low NK cells 
(p = 0.05). As expected, increased lymphocyte counts in 
both groups were at the expense of an increased number 
of PB CD56low NK cells (p ≤ 0.001 vs. healthy donors), 
in both absolute and relative numbers (Table 1); of note, 
the increase in the percentage of NK cells from all PB 
lymphocytes, was significantly higher among those 
patients in whom clonality was confirmed vs. polyclonal 
cases (Table 1).
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Table 1: Clinical and laboratory characteristics of subjects with monoclonal vs. polyclonal 
expansions of PB CD56low NK cells vs. normal CD56low NK cells 
 Healthy adults (n = 10) Cases with expanded/aberrant CD56low NK cells P-value
Polyclonal cases (n = 14) Monoclonal cases (n = 9)
Age (years)* 47 ± 24 (27–87) 55 ± 16 (42–83) 54 ± 26 (25–81) NS
Reason for consulting:
 Routine blood analysis NA 83% 80% NS
 General symptoms NA 17% 20% NS
Physical examination:
 Skin lesions 0% 0% 25% NS
Associated autoimmune diseases 0% 0% 13%**§ NS
Laboratory parameters:
 Leukocytosis (>10 × 109/L) 0% 17% 25% NS
 Lymphocytosis (>5 × 109/L) 0% 33% 38% 0.04a
 Lymphocytosis (>3 × 109/L) 0% 58% 100% ≤ 0.05a,b,c,d
 Neutropenia (<1.5 × 109/L) 0% 8% 13% NS
 Anemia (<100g/L) 0% 17% 0% NS
 Thrombocytopenia 
(<100×109/L) 0% 25% 13%
§ NS
PB cell counts*
 Hemoglobin (g/L) 135 ± 17 (160–97) 124 ± 26 (88–186) 139 ± 13 (114–159) NS
 N. of platelets (× 109/L) 233 ± 61 (159–327) 240 ± 120 (79–476) 218 ± 86 (83–346) NS
 WBC count (× 109/L) 6.1 ± 3.1 (4.5–8.2) 7.1 ± 3.4 (3.9–15.5) 8.7 ± 3.6 (4.2–15.4) NS
 N. of neutrophils (× 109/L) 3.6 ± 0.8 (2.4–4.9) 2.6 ± 1.6 (0.9–7.4) 3.2 ± 2.4 (0.3–8.3) 0.02a
 N. of lymphocytes (× 109/L) 1.9 ± 0.7 (0.7–2.8) 3.8 ± 1.9 (1.6–7) 4.7 ± 1.3 (3.1–6.6) ≤ 0.01a,b,c
 N. of CD56low NK cells 
(× 109/L) 0.25 ± 0.1 (0.1–0.4) 1.2 ± 0.6 (0.6–2.2) 2.2 ± 1.2 (0.6–4) ≤ 0.001
a,b,c
% of CD56low NK cells*
 From all PB leucocytes 4.2 ± 1.3 (2–6) 20 ± 7 (7–33) 28 ± 12 (14–43) ≤ 0.001a,b,c
 From PB lymphocytes 13 ± 13 (8–19) 38 ± 10 (20–50) 55 ± 11 (38–67) ≤ 0.003a,b,c,d
Results expressed as percentage of cases or (*) as mean ± one standard deviation (range).
P-values correspond to the following group comparisons:
ahealthy adults vs. both polyclonal plus monoclonal CD56low NK-cell expansions;
bhealthy adults vs. polyclonal CD56low NK-cell expansions;
chealthy adults vs. monoclonal CD56low NK-cell expansions;
dpolyclonal vs. monoclonal CD56low NK-cell expansions.
PB: peripheral blood. NA: not applicable. NS: no statistically significant differences found (p > 0.05).
PB: peripheral blood. WBC: white blood cells.
None of the cases studied showed lymphadenopathies, hepatosplenomegaly and/or associated neoplasias.
§One case diagnosed with immune thrombocytopenia.
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Immunophenotypic features of monoclonal vs. 
normal/reactive polyclonal PB CD56low NK cells
Overall, expanded CD56low NK cells from both 
monoclonal (n = 9) and polyclonal (n = 14) cases showed 
a similar immunophenotypic profile, which was clearly 
different from that of normal PB CD56low NK cells from 
healthy controls: increased levels of CD2, CD57, CD94, 
HLADR, granzyme B and perforin, and lower expression 
of CD7, CD11b, CD38 and the CD161 and CD158b 
killer receptors (p < 0.05) (Figure 1 and Supplementary 
Figure S1). Despite this, expanded CD56low NK cells from 
monoclonal cases showed significantly greater levels of 
both CD94 and HLADR, with also increased percentages 
of both CD94+ and HLADR+ NK cells, versus polyclonally 
expanded CD56low NK cells (p < 0.04) (Figure 1 and 
Table 2). In addition, clonal CD56low NK cells showed a 
pattern of expression of KIR molecules different from that 
of polyclonal CD56low NK cells; accordingly, significantly 
lower percentages of CD158a+ and CD158b+cells, 
together with a higher intensity of expression of CD158e 
were found in the former group (Figure 1). In more 
detail, CD56low NK cells from most monoclonal cases 
did not express any of the KIR molecules investigated 
(≤7% CD56low NK cells were found to be positive for 
CD158a/b/e in 6/9 monoclonal vs. 0/12 polyclonal cases; 
p < 0.05), while CD161 expression was usually restricted 
either to virtually all or ≤ 5% clonal cells (Table 2). In 
contrast, patients with a polyclonal expansion of CD56low 
NK cells usually showed predominant expression of 
one KIR (>50% of CD56low NK cells) molecule in 6/11 
polyclonal cases vs. 1/9 monoclonal cases (Table 2 and 
Supplementary Figure S1). Clonal CD56low NK cells also 
showed significantly lower levels of granzyme B (mean 
fluorescence intensity -MFI- of granzyme B of 160 vs. 98 
for cases with expanded clonal vs. polyclonal NK cells; 
p = 0.03), when compared to expanded polyclonal CD56low 
NK cells. In turn, whereas two cases having clonal 
CD56low NK cells were CD2−, clonal cases showed overall 
significantly higher levels of CD2 and lower amounts 
of CD38/cell vs. both normal and expanded polyclonal 
NK cells (p ≤ 0.002); finally, CD11c levels were greater 
in clonal vs. polyclonally expanded CD56low NK cells 
(p = 0.01) (Figure 1).
In contrast, CD56low NK cells from all three groups 
of subjects displayed stable and similar reactivity for CD8, 
CD45RA and CD45 (Figure 1), in the absence of CD3, 
CD25, CD27, CD28 and CD197 (CCR7).
Identification of the most discriminating 
immunophenotypic markers for the classification 
of CD56low NK cells
Unsupervised hierarchical clustering analysis 
based on 30 immunophenotypic parameters confirmed 
the existence of three different, but partially overlapping 
groups of CD56low NK cells, such unique phenotypic 
profiles being associated with expanded clonal and 
polyclonal NK cells, plus normal PB NK cells, 
respectively (Figure 2). The most relevant parameters for 
the discrimination between monoclonal NK cells from 
both control (normal) and expanded polyclonal NK cells 
included three overexpressed markers (HLADR, CD94 
and CD45RO) and four down-regulated protein-associated 
variables (% CD158a+, % CD161+, % CD11b+ and CD38 
MFI) (Figure 2) among the former group.
A predictive model (PM) based on the above 
referred discriminating parameters was then built 
and evaluated by applying it to the analysis of the 33 
samples of the training set (10 healthy adult donors plus 
9 monoclonal female cases plus 14 polyclonal female 
cases; Figure 3, Panel A). Based on this model, all but 
two samples (31/33; 94%), corresponding to CD94low/
HLADR−/low clonal CD56low NK cells, were correctly 
classified, with a probability of correct classification of 
81% for clonal cases and 98% for polyclonal/normal 
CD56low NK-cell samples. Subsequently, the same PM 
was used to classify the remaining 37 patient samples 
with expansions of CD56low NK cells, in which the 
HUMARA assay could not been performed and/or was 
not informative for the assessment of clonality. From 
these 37 cases, 11 were classified as being clonal and 
26 as polyclonal/normal, with a probability of being 
correctly classified of 90% and 91%, respectively.
To further confirm the value of the above described 
phenotypic markers for the discrimination between 
monoclonal vs. polyclonal CD56low NK cells, the PCA 
(principal component analysis) function of the INFINICYT 
software, was used. Despite clonal cases could not be 
clustered in a single group by PCA, they clearly separated 
from both normal and expanded polyclonal cases when 
phenotypic parameters were considered in the analysis 
(Figure 3, Panel Bg); such discrimination was even more 
clear on PCA when only the two most informative markers 
(HLADR and CD94) were used (Figure 3, Panel Bh). 
Actually, only one clonal case did not cluster separately 
from the group with expanded polyclonal CD56low NK 
cells, due to the fact that NK-cells from this discordant 
case had low CD94 expression levels, in the absence of 
HLADR. The INFINICYT reference data set generated 
upon excluding this case, was then used to classify the 
remaining 37 patient samples containing CD56low NK 
cells of undetermined/unknown clonality (Supplementary 
Figure S2); then, each tested case was evaluated by the 
“fixed” PCA function and assigned to its nearest reference 
entity in the principal component (PC)1 vs. PC2 (APS 
plot in the INFINICYT software) space. Based on this 
approach, 11 cases were classified as monoclonal and 26 
as normal/polyclonal cases, with a 100% concordance 
between the PCA-based and the PM-based classifications.
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Follow-up of CLPD-NK cases predicted to be 
clonal vs. polyclonal on immunophenotypic 
grounds
Clinical and hematological data were collected 
after long-term follow-up (median of 34 months, ranging 
from 3 to 156 months) in a subset of 21/37 CLPD-
NK cases in which both the HUMARA assay and the 
analysis of somatic mutations of STAT3/STAT5b were not 
performed and/or were not informative (9 classified as 
clonal and 12 as polyclonal by the predictive models). 
Interestingly, in all 9 cases with undetermined clonality 
who were predicted to have clonal NK-cells, the absolute 
lymphocyte count remained over the normal range after 
a median follow-up of 29 months; even more, in 2/9 
cases the lymphocyte count increased (from 4.3 to 10.2 
× 109/l and from 4.8 to 8.4 × 109/l). Of note, one of these 
later patients died 4 years after first diagnosis, although 
the actual cause of death was unknown. In contrast, 
in 58% (7/12) of cases predicted to be polyclonal by 
the statistical predictive models described below, the 
lymphocyte count decreased and returned to normal 
values after a median follow-up of 31 months, while it 
remained stable and high in the other 5 cases. Most of 
these "polyclonal" CLPD-NK patients (n = 10/12) had 
no clinical symptoms at follow-up; the two symptomatic 
cases corresponded to two patients diagnosed with cancer 
who died due to their tumors, after NK-cell counts had 
decreased toward normal values.
DISCUSSION
CLPD-NK has been recognized as a new provisional 
diagnostic entity in the WHO2008 classification 
Figure 1: Immunophenotypic characteristics of expanded monoclonal versus expanded polyclonal and normal adult 
peripheral blood CD56low NK cells. Clonality was assessed in all patients included in the analyses displayed (n = 23) by the 
HUMARA assay. CD56low NK cells from the three groups of subjects showed a similar positive reactivity for CD8, CD45RA and CD45, 
while the expression of CD3, CD25, CD27, CD28 and CD197 (CCR7) was systematically negative. Results are expressed for each marker 
as percentage of positive cells (light gray boxes, referred to the scales at the left of the plots) and mean fluorescence intensity - MFI- of 
positive cells - arbitrary relative linear units scaled from 0 to 104 cells (dark gray boxes, referred to the scales at the right of the plots). 
Notches boxes represent 25th and 75th percentile values; the line in the middle and vertical lines correspond to the median value and the 
minimum-maximum values (without the extreme values and outliers), respectively. ¥ Please note that the high expression levels of CD5 for 
clonal cases corresponds only to one case in which 1% of CD56low NK cells were CD5+ with a MFI of 482. # P-value < 0.05 vs. CD56low 
NK cells from the control group (healthy adults).*P-value < 0.05 vs. expanded polyclonal CD56low NK cells.
Oncotarget6www.impactjournals.com/oncotarget
Table 2: Expression of the CD158a/b/e killer-immunoglobulin-like receptors (KIR) and the CD94 
and CD161 C-type lectin-like receptors on peripheral blood CD56low NK cells from patients with 
clonal (n = 9) and polyclonal (n = 12*) expansions of CD56low NK cells
Percentage of CD56low NK cells expressing each marker
CD158a CD158b CD158e CD94 CD161
Clonal#1 20 58 6 100 40
Clonal#2 8 10 8 100 100
Clonal#3 39 20 46 100 87
Clonal#4 0 1 1 100 0
Clonal#5 0 1 1 100 5
Clonal#6 0 3 2 100 0
Clonal#7 1 2 2 100 2
Clonal#8 0 0 0 100 0
Clonal#9 0 7 0 100 100
Median 0 3 2 100 5
Interquartile range 0–14 1–15 0.5–7 100–100 0–93
Minimum-maximum 
values 0–39 0–58 0–46 100–100 0–100
Polyclonal#1 73 23 9 100 57
Polyclonal#2 10 10 0 81 35
Polyclonal#5 14 n.a. 9 47 32
Polyclonal#6 27 28 20 42 25
Polyclonal#7 28 15 11 40 78
Polyclonal#8 46 37 26 34 75
Polyclonal#9 3 43 0 56 n.a.
Polyclonal#10 75 15 6 65 61
Polyclonal#11 58 73 0 75 62
Polyclonal#12 6 76 0 80 20
Polyclonal#13 3 60 18 76 77
Polyclonal#14 29 70 0 72 37
Median 27.5 37 7.5 68.5 57
Interquartile range 7–55 15–70 0–16.3 43.3–79 32–75
Minimum-maximum 
values 3–75 23–76 0–26 34–100 25–78
p-values 0.007 0.003 n.s.  <0.0001 n.s.
n.a.: not available; n.s.: Not statistically significant differences (p > 0.05) between clonal and polyclonal cases.
* In two out of the 14 cases with expanded polyclonal CD56low NK cells, data about more than one killer receptor was not 
available, and therefore, these two cases were excluded from Table 2.
Oncotarget7www.impactjournals.com/oncotarget
Figure 2: Unsupervised hierarchical clustering analysis of the immunophenotypic pattern of expanded monoclonal, 
expanded polyclonal and normal adult peripheral blood (PB) CD56low NK cells. Trees were generated based on the expression 
patterns observed on PB CD56low NK cells for the 30 immunophenotypic variables included in the study, generated using the Cluster and 
TreeView software programs. Panel A. shows the clustering trees of the three groups included in the study, while Panels B, C. and D. show 
the trees generated for the following analyses: healthy adults vs. expanded polyclonal NK-cell cases (B); expanded monoclonal NK-cell 
cases vs. healthy adults (C) and; expanded monoclonal vs. expanded polyclonal patient groups (D), respectively. For each given marker, 
immunophenotypic data is expressed both as percentage of positive cells and as mean fluorescence intensity of positive cells –arbitrary 
relative linear units scaled from 0 to 104cells–, except for CD38 and CD45RA, which are expressed only as MFI values (for a total of 30 
immunophenotypic variables). Columns show the expression levels for a single sample; rows represent the relative levels of expression for 
a single immunophenotypic parameter, centered at the geometric mean of the expression levels observed for all samples. Red and green 
colors indicate values higher or lower than the mean, respectively; color intensity represents the magnitude of the deviation from the mean; 
black color represents no significant change in the expression levels for that sample vs. the mean.
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Figure 3: Identification of the most relevant phenotypic markers contributing to the discrimination between normal/
polyclonal and monoclonal peripheral blood CD56low NK cells. Panel A. illustrates the “Nearest-shrunken centroid” analysis, 
showing the shrunken differences for the 7 immunophenotypic markers having at least 1 non-zero difference, selected as significant by SAM 
analysis. Left-sided and right-side bars indicate lower and higher expression in each group with respect to the overall centroid, respectively. 
Markers are ordered from the greatest to the smallest difference. Numbers in brackets indicate d-Values: positive d-Values denote over-
expression on clonal CD56low NK cells, while negative d-Values indicate under-expression on clonal CD56low NK cells. Panel B. shows 
pairwise PCA-based comparisons of the phenotypes of expanded monoclonal, expanded polyclonal and normal adult peripheral blood CD56low 
NK cells. APS -Automated Population Separator function included in the INFINICYT software, corresponding to the principal components 1 
(X axis) and 2 (y axis)- views showing the discrimination between CD56low NK cells from: healthy adults (blue circles) vs. reactive polyclonal 
(orange circles) cases (a and b); healthy adults (blue circles) vs. clonal (red circles) cases (c and d); clonal (red circles) vs. polyclonal (orange 
circles) (e and f); and clonal (red circles) vs. both healthy adults and reactive (green circles) cases (g and h). Each circle represents one single 
case (median expression observed for all the phenotypic parameters evaluated). Contour lines in these plots represent one standard deviation 
curves. Panels a, c, e and g show mean principal component 1 vs. principal component 2 values for each case, considering all phenotypic 
parameters analyzed; the first four parameters contributing to the best discrimination between the two groups (ordered according to their 
percentage of contribution) are displayed at the bottom of each plot. Panels b, d, f and h show mean principal component 1 vs. principal 
component 2 values for each case, but considering only the CD94 and HLADR parameters. The arrow denotes the only misclassified case.
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of hematopoietic tumors, these cases being clearly 
different from aggressive mature NK-cell neoplasms 
such as extranodal NK/T cell lymphoma, nasal type and 
aggressive NK cell leukemia (ANKL) [11, 30, 31]. CLPD-
NK usually shows an indolent clinical behavior; however, 
far from being a homogeneous group of diseases, CLPD-
NK encompasses truly leukemic cases, some of which 
even show transformation to ANKL [32, 33], and reactive 
conditions, which might likely represent the extreme pole 
of an immunologic response to unknown stimuli [10]. In 
contrast to chronic expansions of clonal vs. reactive B and 
T cells, which can be more easily distinguished based on 
the analysis of the immunoglobulin/T-cell receptor gene 
rearrangements, CLPD of clonal vs. polyclonal NK cells 
are rather difficult to diagnose, among other reasons, 
because of the lack of a universal and specific marker for 
NK- cell clonality. This also concerns detection of STAT3 
somatic mutations which have recently been identified as a 
recurrent genetic abnormality in patients with CLPD-NK, 
since they are only present in between 18% and 30% of 
cases by conventional sequencing techniques [27, 34], in 
line with our findings. The challenge that assessment of 
clonality represents in CLPD-NK, together with the rarity 
of NK-cell tumors, undoubtedly have hampered our ability 
to standardize the diagnostic procedures for this entity, and 
hence, the clinical management of CLPD-NK patients.
At present, it is well-established that in most 
hematological malignancies (e.g. acute leukemias, B- and 
T-cell CLPD and plasma cell disorders) neoplastic cells 
from virtually every patient display aberrant phenotypes, 
that can be used for the distinction of such tumor cells 
from their normal counterparts [35, 36,]. Of note, such 
aberrant phenotypes are not exclusive of malignant 
leukemias and lymphomas, as they can be also found at 
similar frequencies in benign conditions, e.g. monoclonal 
B-cell lymphocytosis (MBL) [37] and monoclonal 
gammapathy of undetermined significance (MGUS) [38]. 
Consequently, the "leukemia-associated phenotypes" can 
also be considered to represent markers for clonality. 
Based on this hypothesis, here we investigated for the first 
time the utility of a broad panel of immunophenotypic 
markers assessed by flow cytometry, as surrogate 
markers for the classification of CLPD of CD56low NK 
cells into clonal vs. polyclonal cases. For this purpose, 
we comparatively analyzed the immunophenotypic 
profile of PB CD56low NK cells from female patients in 
whom the clonal vs. polyclonal nature of the expanded 
cells was previously known (e.g. by the HUMARA 
X-chromosome inactivation assay performed on highly 
purified cells) to that of normal adult PB CD56low NK 
cells. Phenotypic analyses included a large panel of NK-
cell-associated markers, consisting of signaling (e.g. CD2, 
CD5, CD7, CD8) and adhesion molecules (e.g CD11b 
and CD11c), activation-related markers (e.g. CD38, 
CD45RO and HLADR), IL2 receptors (e.g. CD25 and 
CD122), maturation-associated proteins (e.g. CD57), 
cytotoxic enzymes (e.g. granzyme B and perforin) and 
receptors involved in the recognition of target cells (e.g. 
CD16, the CD158a, CD158b and CD158e natural-killer 
immunoglobulin-like receptors –KIR- and the CD94 
and CD161 C-type lectin-like receptors), among other 
molecules. Based on the above referred markers, expanded 
CD56low NK cells from both monoclonal and polyclonal 
patients showed an overlapping immunophenotypic profile 
consistent with that of late-stage activated NK cells [5], 
which was clearly different from the one displayed by 
normal CD56low NK cells. These findings support the 
hypothesis that both clonal and polyclonally expanded NK 
cells could emerge as a consequence of chronic antigen 
stimuli. In this regard, CD56low NK cells from CLPD 
patients showed higher expression of CD57, granzyme 
B and perforin than normal control cells, together with a 
CD2high/CD7low phenotypic pattern, upregulation of CD94 
and HLADR and lower expression of CD11b, CD38 and 
CD161; while the former marker profile is typical of late-
maturation stage cells, the later is usually featured on 
activated NK cells [5].
Recent studies have evaluated the expression profile 
of natural cytotoxicity receptors [24] and different killer 
cell immunoglobulin-like receptors [21, 31], showing 
a skewed repertoire of KIR receptors on the expanded 
cells from CLPD-NK patients [24, 29]; in turn, others 
have reported bright CD94 expression on pathological 
cells from CLPD-NK patients [24, 29]. However, despite 
the biological findings and the interest of these reports, 
in none of them the monoclonal vs. polyclonal nature of 
the expanded NK cells was investigated, in contrast to 
what was achieved here. Thus, the potential contribution 
of immunophenotyping to the differential diagnosis 
between expanded clonal and polyclonal CD56low NK 
cells in CLPD-NK, would be of utmost clinical relevance, 
specially if we take into account that there were no 
significant clinical differences between the two patient 
groups, in line with previous observations [7, 8, 40]. 
In this regard, and despite the similarities between the 
expanded clonal and polyclonal NK cells, detailed analysis 
of the pattern of expression of individual markers already 
highlighted significant differences between the two 
patient groups, including a greater expression of CD94 
and HLADR (both in terms of percentage of cells and 
expression levels/cell of both markers), as well as CD2, 
together with lower positivity for the CD158a/b/e KIR 
molecules, CD38 and granzyme B in expanded clonal 
vs. polyclonal CD56low NK cells. Of note, expanded 
CD56low NK cells from most monoclonal cases lacked on 
expression of all KIR investigated, in contrast to normal/
polyclonal NK cells from both reactive cases and healthy 
controls; these findings support and extend on previous 
studies that reported a skewed KIR repertoire for LGL-NK 
cell leukemias vs. normal NK cells [24]; in addition, here 
we show for the first time that most expanded CD56low 
NK cells from individual reactive/polyclonal cases usually 
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expressed one single (exceptionally two) KIR molecules, 
a feature that others have considered as a surrogate 
marker for clonality [24]. Further studies including a 
higher number of KIR and other killer receptor molecules 
analyzed on larger series of patients with CD56low NK-
cell expansions vs. healthy donors would be required, to 
definitively clarify this apparent discrepancy.
In order to identify a more robust NK-cell 
phenotypic profile that could be prospectively applied 
to the diagnosis of clonality in CLPD-NK patients, 
multivariate analyses were performed. As a result, 
unsupervised hierarchical clustering analysis showed that 
the most relevant parameters contributing to the distinction 
between monoclonal vs. both expanded polyclonal 
and normal CD56low NK cells included overexpression 
of HLADR and CD94, together with CD45RO, and 
downregulation of CD158a, CD38, CD11b and CD161. 
Based on these markers, cases were segregated into 
three groups, polyclonal/reactive CLPD-NK cases being 
located between the normal and the monoclonal NK-cell 
groups. Based on these results, a predictive model was 
constructed using the above markers and the training set 
of cases; such model provided to properly classify all but 
two clonal CLPD-NK cases, whose CD56low NK cells 
did not express high levels of HLADR and CD94. These 
observations also indicated that the phenotypic profile 
that would mostly contribute to the diagnosis of clonality 
of CLPD-NK strongly relies on the existence of a strong 
and more homogeneous expression of both HLADR and 
CD94, in such a way that when clonal NK cells show a 
different HLA-DR/CD94 profile, a high overlap with the 
phenotype of polyclonal (particularly reactive) NK cells 
might exist. This was further confirmed by PCA, which 
showed that the two most useful phenotypic parameters for 
the identification of clonal vs. normal/polyclonal CD56low 
NK cells were HLADR and CD94. Actually, only one 
clonal case did not cluster separately from the expanded 
polyclonal CD56low NK-cell group in the PCA, such a case 
showing a CD94low/HLADRlow immunophenotypic profile.
More interestingly, when the two predictive models 
were applied for the prospective classification of the 37 
CLPD-NK cases in which the HUMARA assay could not 
be performed and/or it was not informative, they showed 
a 100% concordance for the classification of this group 
of cases into the monoclonal (n = 11) and the polyclonal 
(n = 26) NK-cell categories. Follow-up of most of 
these patients was highly concordant with the predicted 
monoclonal vs. polyclonal nature of the expanded PB 
CD56low NK cells at diagnosis. Thus, in two patients 
predicted to have clonal NK-cells the absolute number 
of lymphocytes is increased with time, while in all other 
cases from this group kept stable over the normal range; in 
contrast, the lymphocyte count returned to normal values 
in near two thirds of cases predicted to be polyclonal and 
remained stable in the other third.
Altogether, these results provide the basis for 
prospective usage of altered NK-cell immunophenotypes, 
in the absence of other universal markers for NK-cell 
clonality, as a surrogate marker for the distinction between 
clonal and reactive NK-cell expansions in the diagnostic 
work-up of CLPD-NK. The most discriminating 
phenotypic profile that contributed to such distinction 
consist of a strong and more homogeneous expression 
of CD94 and HLADR and, to a lesser extent also, 
downregulation of CD158a, CD38, CD11b and CD161.
MATERIALS AND METHODS
Patients and samples
A total of 60 patients who showed increased 
numbers of circulating PB CD56low NK cells, referred to 
the Cytometry Service of the University of Salamanca 
during a 12-year period of time, were studied. Median 
age of the patients -29 males and 31 females- was of 65 
years (range: 25 to 86 years). Inclusion criteria were: 
presence of increased numbers of PB CD56low NK cells 
(>2 × 109/L and/or > 20% NK cells from all circulating 
lymphocytes), for more than 6 months, or identification 
of phenotypically aberrant CD56low NK cells, regardless 
of their actual numbers. An additional group of 10 adult 
healthy volunteers (3 males and 7 females; median age 
of 47 years, ranging from 27 to 83 years) with normal 
blood cell counts, in the absence of any apparent or known 
disease was also included in the study.
PB samples from both the patients and the controls 
were collected into tubes containing K3-EDTA, after 
written informed consent was given by each subject, 
according to the Declaration of Helsinki. The study was 
approved by the Ethics Committee of the University 
Hospital of Salamanca (Salamanca, Spain).
Flow cytometry immunophenotypic studies
Enumeration of PB lymphoid cell subsets, 
including CD56low NK cells, was performed using the 
LymphoclonalTM reagent (Cytognos SL, Salamanca, 
Spain), which contains a mixture of seven antibodies (Ab) 
[fluorescein isothiocyanate (FITC)/phycoerythrin (PE)/ 
peridin chlorophyll protein-cyanin 5.5 (PerCP-Cy5.5)/
allophycocyanin (APC)]: anti-human immunoglobulin 
light chain λ (Igλ) + CD8/anti-human Igκ + CD56/CD19 
+ CD4/CD3. Further immunophenotypic characterization 
of PB CD56low NK cells was performed using the 
following 4-color combinations of fluorochrome-
conjugated -FITC/ PE/ PE-cyanin 5 (PE-Cy5) or PerCP-





CD56/CD3; CD16/CD158e (NKB1)/CD56/CD3; CLA/
CD158b (NKAT2)/CD56/CD3; CD158a (NKAT1)/
CD161/CD56/CD3; CD122/CD25/CD56/CD3 and 
cytoplasmic (Cy) perforin/Cy granzyme B/CD56/CD3. 
The sources and specificities of the MAb reagents used 
have been previously described in detail [26, 28]. Cell 
staining was performed on whole blood samples, using a 
well-established stain-and-then-lyse method, as previously 
reported [26, 28]. Combined staining for surface antigens 
and intracellular molecules was performed using the Fix 
& PermTM reagent kit (Invitrogen, Carlsbad, CA, USA), 
according to the recommendations of the manufacturer. 
Data acquisition was performed immediately after 
completion of sample preparation, in a FACSCalibur flow 
cytometer -Becton Dickinson Biosciences (BD), San Jose, 
CA, USA- using the CellQUESTTM software program 
(BD). For data analysis, the INFINICYTTM software 
program (Cytognos), was used. In each case, CD56low NK 
cells were defined as those CD56low/CD3− events included 
in a broad forward (FSC) vs. sideward light scatter (SSC) 
lymphocyte region. For each antigen analyzed, both the 
percentage of positive CD56low NK cells and its intensity 
of expression -reflected by the MFI expressed in arbitrary 
relative linear units scaled from 0 to 104-, were evaluated.
HUMARA assay
In order to confirm the monoclonal vs. polyclonal 
nature of the expanded/aberrant CD56low NK cells, 
the pattern of inactivation of the human androgen 
receptor coded in chromosome X was studied in 
25/31 female patients. The methylation status of the 
human androgen receptor gene was evaluated with a 
HUMARA polymerase chain reaction (PCR)-based 
assay [25, 41, 42, 43] for paired fractions of purified 
CD56low NK cells (mean purity of 98% ± 1.2%; range: 
94% to 99%) and the corresponding NK-cell depleted 
leukocyte fraction from the same subject (n = 25). NK 
cells were purified from mononuclear PB cells (obtained 
after Ficoll-PaqueTM density gradient centrifugation) 
by a single immunomagnetic depletion step using the 
Human NK-Cell Enrichment Kit (StemStepTM, StemCell 
Technologies Inc, Vancouver, BC, Canada) and an 
AutoMACS magnetic cell separator (Miltenyi Biotec, 
Bergisch Gladbach, Germany), strictly following 
the recommendations of the manufacturer. Purified 
populations were used to extract genomic DNA (gDNA) 
using the QIAamp mini- or micro-DNA extraction 
Kits (QIAGEN, Valencia, CA). Digestion of genomic 
DNA was performed with the HapII methylation-
sensitive restriction endonuclease and subsequent PCR 
amplification of the methylated (inactivated) alleles, as 
previously described [25, 41, 42]. According to previous 
reports, a case was considered to be monoclonal when 
the corrected allele ratio was of ≤0.33 or ≥3, indicating 
that one of the parental alleles was represented at an 
excess of ≥50% vs. the other allele [43].
Analysis of STAT3 and STAT5b somatic 
mutations
STAT3 and STAT5b gene mutations were analyzed 
on gDNA extracted from highly purified CD56low NK cells 
-according to the techniques described above- from a total 
of 9 cases which had also been evaluated by the HUMARA 
assay, from which 4 corresponded to monoclonal and 5 
to polyclonal cases. Previously reported PCR primers 
were used to amplify known somatic mutational hotspot 
regions in the STAT3 and STAT5b genes, located at 
STAT3 SH2 exons 19–20 and 21, as well as at STAT5b 
SH2 exon 16 [27, 34, 44). The amplified products were 
sequenced by conventional techniques at the Genomic 
Unit of the Cancer Research Center (IBMCC, USAL-
CSIC, Salamanca, Spain); all mutations were screened 
by bidirectional sequencing and scored as pathogenic 
mutations on the basis of the observation that they were 
not detected in paired cell subsets other than NK cells. 
The sequences were analyzed using the Chromas Lite 
Sequencing Software (South Brisbane, Australia).
Statistical methods
Conventional statistics –nonparametric Kruskal-
Wallis and Mann-Whitney U tests for continuous 
variables, or the Pearson’s χ2 and Fisher exact tests for 
categorical variables– were performed using the SPSS 
software program (IBM SPSS Statistics, IBM, Armonk, 
NY, USA). P values ≤ 0.05 were considered to be 
associated with statistical significance.
Multivariate analysis of markers differentially 
expressed in normal and reactive vs. clonal CD56low NK 
cells was performed in four consecutive steps. Only 
healthy subjects (n = 10) and those female patients found 
to be heterozygous for the HUMARA assay (n = 23 
female cases tested; 9 monoclonal and 14 polyclonal) were 
included in the analysis. Prior to the analysis, data about 
the immunophenotype of CD56low NK cells – percentage of 
cells positive for each individual marker, as well as the MFI 
values of CD56low NK cells positive for each marker (n = 30 
variables)– was normalized using the mean value obtained 
for each individual variable in normal PB NK cells and 
logarithmically (base 2) transformed. Afterward (step 1), 
both unsupervised and supervised hierarchical clustering 
analyses based on the average-linkage method and an 
Euclidean metric [45] were applied (Cluster 3.0 and Tree 
View software, Stanford University, Stanford, CA, USA) 
[46]. In a second step, a Significant Analysis of Microarrays 
(SAM) algorithm was built -with the same 30 variables 
used in step 1- in order to identify those markers showing 
a statistically significantly different expression in the clonal 
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(n = 9) vs. polyclonal classes (n = 14 cases plus 10 healthy 
controls). Data was permutated over 100 cycles by using 
the two-class (unpaired) format and the statistically relevant 
variables (T-test) were selected, based on the lowest false 
discovery ratio (FDR < 2.2) and the q-value (0) [47] 
obtained. In the following step (third step), those variables 
identified to be significantly associated with different 
classes were used to build a class predictor (weighted 
voting algorithm with a leave-one-out cross validation), 
that included the smallest combination of variables for 
correct classification of CD56low NK-cell expansions as 
monoclonal vs. polyclonal. A training set containing all 
above referred 33 cases (10 healthy adult donors plus 9 
monoclonal female cases plus 14 polyclonal female cases) 
was used to train the classifier, and the accuracy of the 
predictor was subsequently tested in a set including all the 
60 patients studied and who presented with abnormal NK-
cell numbers and/or phenotypes, using the nearest shrunken 
centroids method (PAM software; University of Stanford, 
Stanford, CA, USA) [48]. In the last (fourth) step, principal 
component analysis (PCA) was applied to flow cytometric 
data from individual cells, in order to confirm the value of 
the individual variables selected for correct classification 
of monoclonal vs. polyclonal nature of a given expansion 
of CD56low NK cells. For this purpose, a reference data set 
was built with data from healthy controls (n = 10) and those 
patients proved to have polyclonal (n = 14) and monoclonal 
(n = 9) NK-cell expansions by the HUMARA assay, using 
the merge and calculation functions of the INFINICYTTM 
software, as previously described [49]. Unsupervised PCA 
was then performed for the reference database and data was 
then visualized in a 2-dimensional plot defined by the first 
(PC1) vs. second (PC2) principal component (APS plot 
in the INFINICYT software) [50, 51] for the distinction 
among different clusters of NK cells.
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